Spero Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Spero Therapeutics Inc (SPRO)

Q3 202619 Jun – 14 Jul 2026

▲3

Spero wins FDA approval for Utebzi and secures $105M for immunology push

FDA approval of Utebzi The FDA approved Utebzi, the first oral carbapenem for complicated UTIs, developed with GSK. This is a major regulatory win that opens a new market and could bring milestone and royalty payments to Spero, boosting its long-term revenue potential.
This is the key regulatory event that validates Spero's partnered drug and creates a new revenue stream.
$105M non-dilutive financing Spero secured $105 million from KKR's Healthcare Royalty, extending its cash runway into 2029. This non-dilutive funding avoids selling new shares and provides capital to advance its immunology candidate SP001, strengthening the balance sheet.
This financing directly addresses Spero's capital needs and funds future growth without diluting shareholders.
Licensing deal for IBI355 Spero licensed IBI355, a third-generation anti-CD40L antibody, from Innovent for up to $1.1 billion in milestones. This expands Spero's immunology pipeline with a promising drug and shows confidence in its development strategy, potentially driving future value.
This deal adds a new pipeline asset and significant potential milestone payments, enhancing Spero's growth prospects.

July 202619 Jun – 14 Jul 2026

▲3

Spero wins FDA approval for Utebzi and secures $105M for immunology push

FDA approval of Utebzi The FDA approved Utebzi, the first oral carbapenem for complicated UTIs, developed with GSK. This is a major regulatory win that opens a new market and could bring milestone and royalty payments to Spero, boosting its long-term revenue potential.
This is the key regulatory event that validates Spero's partnered drug and creates a new revenue stream.
$105M non-dilutive financing Spero secured $105 million from KKR's Healthcare Royalty, extending its cash runway into 2029. This non-dilutive funding avoids selling new shares and provides capital to advance its immunology candidate SP001, strengthening the balance sheet.
This financing directly addresses Spero's capital needs and funds future growth without diluting shareholders.
Licensing deal for IBI355 Spero licensed IBI355, a third-generation anti-CD40L antibody, from Innovent for up to $1.1 billion in milestones. This expands Spero's immunology pipeline with a promising drug and shows confidence in its development strategy, potentially driving future value.
This deal adds a new pipeline asset and significant potential milestone payments, enhancing Spero's growth prospects.

Latest19 Jun – 14 Jul 2026

▲3

Spero wins FDA approval for Utebzi and secures $105M for immunology push

FDA approval of Utebzi The FDA approved Utebzi, the first oral carbapenem for complicated UTIs, developed with GSK. This is a major regulatory win that opens a new market and could bring milestone and royalty payments to Spero, boosting its long-term revenue potential.
This is the key regulatory event that validates Spero's partnered drug and creates a new revenue stream.
$105M non-dilutive financing Spero secured $105 million from KKR's Healthcare Royalty, extending its cash runway into 2029. This non-dilutive funding avoids selling new shares and provides capital to advance its immunology candidate SP001, strengthening the balance sheet.
This financing directly addresses Spero's capital needs and funds future growth without diluting shareholders.
Licensing deal for IBI355 Spero licensed IBI355, a third-generation anti-CD40L antibody, from Innovent for up to $1.1 billion in milestones. This expands Spero's immunology pipeline with a promising drug and shows confidence in its development strategy, potentially driving future value.
This deal adds a new pipeline asset and significant potential milestone payments, enhancing Spero's growth prospects.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.